Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Niagen Bioscience (NAGE) Research & Development (2016 - 2025)

Historic Research & Development for Niagen Bioscience (NAGE) over the last 11 years, with Q3 2025 value amounting to $1.8 million.

  • Niagen Bioscience's Research & Development rose 3914.73% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year increase of 127.99%. This contributed to the annual value of $6.0 million for FY2024, which is 2133.92% up from last year.
  • Latest data reveals that Niagen Bioscience reported Research & Development of $1.8 million as of Q3 2025, which was up 3914.73% from $1.6 million recorded in Q2 2025.
  • In the past 5 years, Niagen Bioscience's Research & Development ranged from a high of $2.1 million in Q1 2024 and a low of $787000.0 during Q1 2021
  • Moreover, its 5-year median value for Research & Development was $1.2 million (2022), whereas its average is $1.3 million.
  • Its Research & Development has fluctuated over the past 5 years, first surged by 7560.77% in 2024, then crashed by 3995.23% in 2025.
  • Over the past 5 years, Niagen Bioscience's Research & Development (Quarter) stood at $1.0 million in 2021, then increased by 22.39% to $1.3 million in 2022, then fell by 9.38% to $1.2 million in 2023, then grew by 13.46% to $1.3 million in 2024, then surged by 36.5% to $1.8 million in 2025.
  • Its last three reported values are $1.8 million in Q3 2025, $1.6 million for Q2 2025, and $1.3 million during Q1 2025.